Early cancer of digestive system tumors usually has no typical symptoms. Once found, most of them are in the middle and late stage of cancer, with high mortality, poor prognosis, short survival time and high heterogeneity. The occurrence of digestive system tumors is a complex process with multiple gene mutations and multi-step regulation. At present, there is still a lack of specific molecular targeted drugs and early screening diagnostic markers. Systematic and in-depth study of the driver mutations and epigenetic modifications of the genome of digestive system tumors will be of positive significance for elucidating the molecular mechanism of digestive system tumors, as well as for their early diagnosis, prevention and treatment. High-throughput sequencing technology combined with bioinformatics analysis provides a powerful means for comprehensive and systematic analysis of tumor genomic characteristics. The use of omics data to analyze the mechanism of tumor development is more holistic and comprehensive, which will help many patients benefit from molecular target for early diagnosis and treatment.
More and more attention has been paid to multi-omics research, and single-target treatment of tumors has become the past. In the future, the frontier trend of this field at home and abroad is multi-target, multi-pathway, and even multi-disciplinary combined treatment. Including, but not limited to, epigenetic regulation of digestive system tumors, non-coding RNA roles in digestive system tumors, cancer stem cells in digestive system tumors, genetic risk factors of digestive system tumors, chromosome, gene, DNA variation and microenvironment genetics of digestive system tumors, targeted therapy of digestive system tumors, pharmacogenetics for optimizing the treatment of digestive system tumors, biomarkers and immunotherapy of digestive system tumors, etc.
The original research and review papers focusing on, but not limited to, the following:
• Somatic genomic variants in digestive system tumors
• Microenvironment, molecular analysis in digestive system tumors
• To analyze the cancer subtypes of digestive system tumors and predict the prognosis of cancer based on artificial intelligence multi-omics
• Epigenetic changes and the signal interaction mechanisms in the development of digestive system tumors
• To identify the key target genes or signaling pathways of digestive system tumors, and to explore their potential mechanisms for the prevention and treatment of metastasis and drug resistance of digestive system tumors
• Target discovery and testing for small-molecule drugs
• New tumor imaging probes, molecular imaging, PET imaging probes and other diagnostic strategies
Keywords:
digestive system carcinoma, molecular diagnosis, molecular pathogenesis, targeted therapy, tumorigenesis
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Early cancer of digestive system tumors usually has no typical symptoms. Once found, most of them are in the middle and late stage of cancer, with high mortality, poor prognosis, short survival time and high heterogeneity. The occurrence of digestive system tumors is a complex process with multiple gene mutations and multi-step regulation. At present, there is still a lack of specific molecular targeted drugs and early screening diagnostic markers. Systematic and in-depth study of the driver mutations and epigenetic modifications of the genome of digestive system tumors will be of positive significance for elucidating the molecular mechanism of digestive system tumors, as well as for their early diagnosis, prevention and treatment. High-throughput sequencing technology combined with bioinformatics analysis provides a powerful means for comprehensive and systematic analysis of tumor genomic characteristics. The use of omics data to analyze the mechanism of tumor development is more holistic and comprehensive, which will help many patients benefit from molecular target for early diagnosis and treatment.
More and more attention has been paid to multi-omics research, and single-target treatment of tumors has become the past. In the future, the frontier trend of this field at home and abroad is multi-target, multi-pathway, and even multi-disciplinary combined treatment. Including, but not limited to, epigenetic regulation of digestive system tumors, non-coding RNA roles in digestive system tumors, cancer stem cells in digestive system tumors, genetic risk factors of digestive system tumors, chromosome, gene, DNA variation and microenvironment genetics of digestive system tumors, targeted therapy of digestive system tumors, pharmacogenetics for optimizing the treatment of digestive system tumors, biomarkers and immunotherapy of digestive system tumors, etc.
The original research and review papers focusing on, but not limited to, the following:
• Somatic genomic variants in digestive system tumors
• Microenvironment, molecular analysis in digestive system tumors
• To analyze the cancer subtypes of digestive system tumors and predict the prognosis of cancer based on artificial intelligence multi-omics
• Epigenetic changes and the signal interaction mechanisms in the development of digestive system tumors
• To identify the key target genes or signaling pathways of digestive system tumors, and to explore their potential mechanisms for the prevention and treatment of metastasis and drug resistance of digestive system tumors
• Target discovery and testing for small-molecule drugs
• New tumor imaging probes, molecular imaging, PET imaging probes and other diagnostic strategies
Keywords:
digestive system carcinoma, molecular diagnosis, molecular pathogenesis, targeted therapy, tumorigenesis
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.